“
TL;DR
It suggests that targeting senescent cells or their SASP could be a future therapeutic strategy to limit metastasis.
Cells · 3 authors, 5 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It suggests that targeting senescent cells or their SASP could be a future therapeutic strategy to limit metastasis.
This narrative review examines the proposed role of cellular senescence in metastatic cancer. The authors describe how senescent cells, via their Senescence-Associated Secretory Phenotype (SASP) and metabolic adaptations, may promote cancer cell invasion, survival during dissemination, and colonization of secondary organs. The review discusses potential therapeutic strategies, such as SASP inhibitors (e.g., rapamycin, metformin) and senolytic agents, which have shown promise in animal models. Limitations include the reliance on indirect, preclinical evidence and many unanswered biological questions. The implications are that dissecting senescence heterogeneity could lead to new cancer therapies, but this remains a future goal.